Athira Pharma Ownership
| ATHA Stock | USD 0.33 0.02 6.06% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 38.5 M | Current Value 38.5 M | Avarage Shares Outstanding 31.9 M | Quarterly Volatility 11.6 M |
Athira |
Athira Stock Ownership Analysis
About 52.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Athira Pharma recorded a loss per share of 2.52. The entity had not issued any dividends in recent years. Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company was incorporated in 2011 and is headquartered in Bothell, Washington. Athira Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. For more info on Athira Pharma please contact Dr MBA at 425 620 8501 or go to https://www.athira.com.Besides selling stocks to institutional investors, Athira Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Athira Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Athira Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Athira Pharma Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Athira Pharma are currently held by insiders. Unlike Athira Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Athira Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Athira Pharma's insider trades
Athira Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Athira Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Athira Pharma backward and forwards among themselves. Athira Pharma's institutional investor refers to the entity that pools money to purchase Athira Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 320.8 K | Gsa Capital Partners Llp | 2024-12-31 | 296.6 K | Two Sigma Advisers, Llc | 2024-12-31 | 253.3 K | Renaissance Technologies Corp | 2024-12-31 | 207.3 K | Royal Bank Of Canada | 2024-12-31 | 183 K | Laird Norton Tyee Trust Co | 2024-12-31 | 127.3 K | State Street Corp | 2024-12-31 | 107.4 K | Ubs Group Ag | 2024-12-31 | 87 K | Advisor Group Holdings, Inc. | 2024-12-31 | 81.3 K | Perceptive Advisors Llc | 2024-12-31 | 5.4 M | Bml Capital Management Llc | 2024-12-31 | 2.8 M |
Athira Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Athira Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Athira Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Athira Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Athira Pharma Outstanding Bonds
Athira Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Athira Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Athira bonds can be classified according to their maturity, which is the date when Athira Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.